(MedPage Today) — The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy (TA-TMA) in adults and kids ages 2 years and up, said maker Omeros on Wednesday…
Source link : https://www.medpagetoday.com/transplantation/transplantation/119200
Author :
Publish date : 2025-12-24 19:12:00
Copyright for syndicated content belongs to the linked Source.
